People across the country are pursuing PPI stomach cancer lawsuits alleging that the makers of popular proton pump inhibitors (PPIs) — including Nexium and Prilosec — knew that long-term use of these heartburn medications could cause stomach cancer and failed to warn patients and the medical community.
Proton pump inhibitors are among the most widely used drugs in the United States. A growing body of medical research links years of PPI use to a higher risk of stomach cancer, and the first individual lawsuits are now moving through the courts.
If you or someone in your family was diagnosed with stomach cancer after using a PPI, you may qualify for a lawsuit against the manufacturer. Wisner Baum is investigating and filing these claims nationwide. Call (310) 207-3233 or contact us for a free, confidential case evaluation.
Proton pump inhibitors (PPIs) are a class of drugs that sharply reduce the amount of acid the stomach produces. They work by blocking the “proton pump,” the part of the stomach's cells that pushes out acid. Doctors prescribe PPIs for conditions such as GERD (gastroesophageal reflux disease), chronic acid reflux, heartburn, peptic ulcers, and other acid-related problems.
The first PPI, Prilosec (omeprazole), reached the U.S. market in 1989. Since then, PPIs have become one of the most commonly used medication classes in the country, sold both by prescription and over the counter. Common brand names include:
These drugs are widely used, and people often take them for long periods of time. More than 15 million Americans used prescription PPIs in 2013, at a cost of over $10 billion — and that figure does not include the millions more who buy PPIs over the counter.
Research suggests that a large share of PPI prescriptions — by some estimates between 25% and 70% — are written for uses or durations that were never properly tested or approved, meaning many people take these drugs far longer than intended.
When a PPI shuts down stomach acid, the body reacts by producing more of a hormone called gastrin. Over the long term, this can lead to hypergastrinemia — abnormally high gastrin levels in the blood. Gastrin is a growth-promoting hormone, and researchers have long recognized that sustained high levels can overstimulate certain stomach cells (called ECL cells), driving them to multiply and, over time, potentially undergo cancerous changes.
Scientists have described a second pathway as well: because PPIs strip away the stomach's protective acid, bacteria can overgrow in the stomach and produce nitrosamines, which are known cancer-causing compounds.
A recent complaint alleges that Nexium's design creates an additional problem. When a patient stops taking the drug, acid production can surge back above normal — a phenomenon called “rebound acid hypersecretion” — which brings back the very symptoms the drug was meant to treat. According to a recently filed complaint, this creates a “dependence loop” that pushes patients into long-term use, and it is long-term use that the lawsuits allege drives the increased cancer risk.
A substantial body of peer-reviewed research has examined the connection between long-term PPI use and stomach cancer:
These studies describe risk across large populations. Whether any one person's cancer was caused by a specific drug is a question decided case by case, based on that individual's medical history and use.
PPIs have been implicated in lawsuits before. However, those cases alleged kidney damage, not stomach cancer. It is important to understand that this litigation is different than previous claims involving kidney injuries.
The earlier PPI kidney litigation was consolidated as MDL No. 2789, In re: Proton-Pump Inhibitor Products Liability Litigation, in the U.S. District Court for the District of New Jersey, before Judge Claire C. Cecchi. The plaintiffs in the PPI kidney damage MDL alleged that PPIs caused injuries such as acute interstitial nephritis, chronic kidney disease, and kidney failure.
In October 2023, AstraZeneca agreed to a $425 million PPI settlement, resolving roughly 11,000 claims involving Nexium and Prilosec. Total PPI kidney settlements — including agreements with GlaxoSmithKline, Procter & Gamble, Pfizer, and Takeda — reached about $590.4 million.
The prior PPI kidney damage settlements do not determine what will happen in the stomach cancer lawsuits, and a diagnosis of stomach cancer — not kidney injury — is what these new claims are built around.
The PPI stomach cancer lawsuits are product liability claims. According to plaintiffs’ attorneys, the drug manufacturers knew — or should have known — for decades that long-term PPI use was linked to gastric cancer, based on animal studies, case reports, and a large body of published research, yet failed to warn patients and doctors. PPI stomach cancer lawsuits allege the following:
According to a filed complaint, the current Nexium label warns prescribers that the drug can mask an existing stomach malignancy, but it does not warn that long-term PPI use may itself be associated with the development of gastric cancer. These are allegations that the plaintiff will need to prove in court.
As of 2026, PPI stomach cancer claims are proceeding as individual lawsuits in federal and state courts — not as a single class action or MDL.
If enough stomach cancer cases are filed, courts may consolidate the claims into a new multidistrict litigation (MDL) in which federally filed cases are consolidated and coordinated for pretrial proceedings.
PPI stomach cancer lawsuits are not a class action. They are individual claims that are likely to become part of a mass tort. In a class action, one group shares a single case and a single outcome. In a mass tort, each person keeps their own separate lawsuit and their own potential recovery, based on their own diagnosis, their own PPI use, and their own damages.
If these cases are eventually grouped into an MDL, that simply means a single federal judge would manage shared pretrial steps — like gathering evidence — for efficiency. Even then, each case stays individual. That structure matters because it means your potential recovery would be tied to the specific injuries in each case, not split evenly across a group.
You may be eligible to pursue a PPI stomach cancer lawsuit if the following generally apply to you or a family member:
Over-the-counter (OTC) PPIs may also qualify, because they contain the same active ingredients as the brand-name drugs. Every situation is different, and the only way to know whether you have a claim is to have an attorney review the details. A free case review can tell you where you stand at no cost or obligation.
Plaintiffs who succeed in a PPI stomach cancer lawsuit may be able to recover compensation for a range of losses. While no outcome can be guaranteed and every case is different, damages in cases like these may include:
For context, PPI manufacturers have paid hundreds of millions of dollars to resolve the earlier kidney-injury claims. While previous PPI settlements involved a different injury and do not predict the value of a stomach cancer lawsuit, they demonstrate that these companies have previously faced accountability.
The PPI stomach cancer lawsuits filed to date have centered on Nexium and Prilosec. However, proton pump inhibitors work via the same acid-suppressing mechanism, and the medical research on gastric cancer risk spans the drug class rather than any single medication. For that reason, Wisner Baum is reviewing and accepting stomach cancer claims involving the full range of PPIs.
Available by prescription and over the counter:
Available by prescription only:
Generic and store-brand versions of these drugs may also qualify, because they contain the same active ingredients. If you took a medication that is not listed here, a PPI lawyer can still review your case.
Filing a PPI stomach cancer lawsuit generally follows a few steps:
Time is a critical factor. Every state sets a statute of limitations — a strict deadline for filing — that generally runs a limited number of years from the date of diagnosis or from when a person reasonably connected the injury to the drug. If that deadline passes, the right to sue can be lost forever. Because these deadlines vary and can be shorter than people expect, it is important to speak with an attorney promptly to protect your rights.
Wisner Baum has represented people harmed by dangerous drugs and defective products since 1985. The firm has earned more than $4 billion in verdicts and settlements for thousands of clients nationwide.
Our trial record includes landmark results against major manufacturers. In the Roundup litigation, managing partner R. Brent Wisner served as co-lead trial counsel in Pilliod v. Monsanto, where a California jury returned a $2.055 billion verdict (later reduced by the court).
Wisner Baum handles these cases on a contingency-fee basis: if we do not win your case, you do not owe us any attorney's fees.
If you or someone you love was diagnosed with stomach cancer after long-term use of Nexium, Prilosec, or another proton pump inhibitor, you may be entitled to compensation. The pharmaceutical attorneys at Wisner Baum are reviewing these claims now. Call (310) 207-3233 or request a free, confidential case evaluation online. There are no fees unless we win your case.
"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.
The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
$289.2 million jury verdict in Monsanto Roundup trial
Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.
Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.
Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
A PPI stomach cancer lawsuit is a product liability claim brought against the makers of proton pump inhibitors like Nexium and Prilosec. Plaintiffs allege that long-term use of these acid-reducing drugs caused their gastric (stomach) cancer and that the manufacturers failed to warn patients and doctors about the risk. Each lawsuit is filed individually on behalf of a person diagnosed with stomach cancer, or their surviving family.
The lawsuits focus on the entire class of proton pump inhibitors, because they share the same acid-suppressing mechanism. This includes brand names such as Nexium, Prilosec, Prevacid, Protonix, Aciphex, and Dexilant, as well as their generic and over-the-counter equivalents.
No. The earlier PPI litigation (MDL 2789 in New Jersey) involved kidney injuries and was largely resolved through settlements, including AstraZeneca's $425 million agreement in 2023. The stomach cancer lawsuits are a separate and newer effort, built on different injuries and different scientific evidence. A stomach cancer diagnosis — not a kidney injury — is what these claims are based on.
Published research points to increased risk with long-term use — often a year or more — with studies reporting higher risk as the dose and duration increase. This is general research across large groups of people and is not medical advice. If you took a PPI long-term and were diagnosed with stomach cancer, an attorney can help you understand whether your history may support a claim.
They may. Over-the-counter PPIs and generic versions contain the same active ingredients as the prescription brand-name drugs, so long-term use of an OTC or generic PPI can potentially support a claim. The strength of any case depends on the individual's use and diagnosis, which an attorney can review during a free consultation.
As of 2026, there is no MDL or class action specifically for PPI stomach cancer claims. These cases are being filed as individual lawsuits. If enough cases are filed, a court could consolidate them into an MDL in the future, but each plaintiff would still keep their own individual case.
Wisner Baum handles PPI stomach cancer cases on a contingency-fee basis. That means there are no upfront costs, and you do not owe any attorney's fees unless we win your case. The initial case evaluation is always free and confidential.
Deadlines to file, called statutes of limitations, vary by state and are often just a few years from the date of diagnosis or from when the injury was reasonably connected to the drug. Because these deadlines can pass quickly, it is important to contact an attorney as soon as possible so you do not lose the right to pursue a claim.
